Amid the coronavirus outbreak, many countries around the world are developing the COVID-19 vaccine. Many vaccines are in the final stages of testing. Meanwhile, the World Health Organization (WHO) has warned about the antiviral drug Remdesivir. The WHO has said that remadecivir should not be used for the treatment of corona patients, regardless of the patient’s condition, because it has “no significant effect” on the chances of survival.
International experts from the WHO Guideline Development Group (GDG) said currently available data provide no evidence that ramdesvir improves patient outcomes.
However, the United States, the European Union and other countries have approved the temporary use of ramdesvir. In the initial research, this step was taken with Remdesiveer after some patients learned that reducing recovery time is helpful.
In October, after the infection of the crown of US President Donald Trump, he received other drugs, including remadecivir.
The WHO recommendation is based on four international randomized trials conducted on more than 7,000 hospitalized corona patients. In the updated Treatment Guide published in BMJ Medical Journal, the expert panel said their recommendation did not mean remadecivir had no benefit for patients.
However, based on the latest data, costs and delivery methods, “remedesivir is not recommended for hospitalized patients with corona infection, regardless of patient severity.”